Oliver's mTOR Atlas Evidence Platform
Reading level
Mode

Xiang Yu

Member of Yanfeng Hu's gastric-cancer lab who contributed to a study showing how a microbiota-linked metabolite, kynurenic acid, drives resistance to PD-1 blockade

Nanfang Hospital, Southern Medical University · Gastric-cancer immunology & microbiome

Xiang Yu is based in Yanfeng Hu's lab at Nanfang Hospital, a group focused on how the gastric tumor microenvironment and its resident microbiota shape immunotherapy response. Xiang Yu co-authored the 2026 study tracing how microbiota-associated kynurenic acid drives resistance to PD-1 blockade through an ITGA2-mTOR-CTSV signaling axis in gastric cancer.

Xiang Yu is first author on a related 2026 Cell Reports Medicine paper from the same lab on bacterial extracellular vesicles enhancing anti-PD-1 efficacy via macrophage FPR1 signaling, and a co-author on other 2024-2025 papers from the same Guangdong Provincial Key Laboratory for GI-tumor precision medicine.

Milestones in the Atlas

A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.

YearEvidenceStudy
2026 A Streptococcus anginosus-associated kynurenic acid drives PD-1 blockade resistance through an ITGA2-mTOR-CTSV axis in gastric cancer. REN2026 Co-author on the study identifying microbiota-derived kynurenic acid as a driver of anti-PD-1 resistance via an ITGA2-mTOR-CTSV axis in gastric cancer.

Co-authors in the Atlas 2

People with a profile here who share at least one study with Xiang Yu.

ShowHide
  • Jiaqiang Jiang Member of the Nanfang Hospital gastric-cancer surgery team that traced how a tumor-enriched gut bacterium rewires CD8+ T cells through an mTOR-linked checkpoint to blunt anti-PD-1 therapy.
  • Yingxin Ren Gastric cancer researcher in Yanfeng Hu's surgical group at Nanfang Hospital who studies how tumour bacteria and metabolism shape resistance to immunotherapy

Every researcher with a profile →

← All researchers

Spotted something wrong or out of date about Xiang Yu?
Was this page useful?